<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="hiv13733" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">HIV Med</journal-id><journal-id journal-id-type="iso-abbrev">HIV Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1468-1293</journal-id><journal-id journal-id-type="publisher-id">HIV</journal-id><journal-title-group><journal-title>HIV Medicine</journal-title></journal-title-group><issn pub-type="ppub">1464-2662</issn><issn pub-type="epub">1468-1293</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39557520</article-id><article-id pub-id-type="pmc">PMC11786617</article-id>
<article-id pub-id-type="doi">10.1111/hiv.13733</article-id><article-id pub-id-type="publisher-id">HIV13733</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Rising mortality among people who inject drugs living with <styled-content style="fixed-case" toggle="no">HIV</styled-content> in <styled-content style="fixed-case" toggle="no">Scotland</styled-content>, <styled-content style="fixed-case" toggle="no">UK</styled-content>: A 20&#x02010;year retrospective cohort study</article-title><alt-title alt-title-type="left-running-head">Metcalfe et al.</alt-title></title-group><contrib-group><contrib id="hiv13733-cr-0001" contrib-type="author" corresp="yes"><name><surname>Metcalfe</surname><given-names>R.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1897-6223</contrib-id><xref rid="hiv13733-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hiv13733-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>becky.metcalfe@nhs.scot</email></address></contrib><contrib id="hiv13733-cr-0002" contrib-type="author"><name><surname>Fraser</surname><given-names>R.</given-names></name><xref rid="hiv13733-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="hiv13733-cr-0003" contrib-type="author"><name><surname>Trayner</surname><given-names>K. M. A.</given-names></name><xref rid="hiv13733-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hiv13733-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hiv13733-cr-0004" contrib-type="author"><name><surname>Glancy</surname><given-names>M.</given-names></name><xref rid="hiv13733-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hiv13733-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hiv13733-cr-0005" contrib-type="author"><name><surname>Yeung</surname><given-names>A.</given-names></name><xref rid="hiv13733-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hiv13733-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hiv13733-cr-0006" contrib-type="author"><name><surname>Sills</surname><given-names>L.</given-names></name><xref rid="hiv13733-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hiv13733-cr-0007" contrib-type="author"><name><surname>Ritchie</surname><given-names>T.</given-names></name><xref rid="hiv13733-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hiv13733-cr-0008" contrib-type="author"><name><surname>Priyadarshi</surname><given-names>S.</given-names></name><xref rid="hiv13733-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hiv13733-cr-0009" contrib-type="author"><name><surname>Peters</surname><given-names>S. E.</given-names></name><xref rid="hiv13733-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="hiv13733-cr-0010" contrib-type="author"><name><surname>McAuley</surname><given-names>A.</given-names></name><xref rid="hiv13733-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hiv13733-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="hiv13733-cr-0011" contrib-type="author"><name><surname>Hutchinson</surname><given-names>S.</given-names></name><xref rid="hiv13733-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="hiv13733-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="hiv13733-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">School of Health and Life Sciences</named-content>
<institution>Glasgow Caledonian University</institution>
<city>Glasgow</city>
<country country="GB">UK</country>
</aff><aff id="hiv13733-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>NHS Greater Glasgow &#x00026; Clyde</institution>
<city>Glasgow</city>
<country country="GB">UK</country>
</aff><aff id="hiv13733-aff-0003">
<label>
<sup>3</sup>
</label>
<institution>Public Health Scotland, UK</institution>
<city>Glasgow</city>
<country country="GB">UK</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>
R. Metcalfe, School of Health and Life Sciences, Glasgow Caledonian University, Cowcaddens Road, Glasgow, UK.<break/>
Email: <email>becky.metcalfe@nhs.scot</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2025</year></pub-date><volume>26</volume><issue seq="120">2</issue><issue-id pub-id-type="doi">10.1111/hiv.v26.2</issue-id><fpage>265</fpage><lpage>274</lpage><history>
<date date-type="received"><day>13</day><month>5</month><year>2024</year></date>
<date date-type="accepted"><day>29</day><month>10</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 British HIV Association--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">HIV Medicine</italic> published by John Wiley &#x00026; Sons Ltd on behalf of British HIV Association.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:HIV-26-265.pdf"/><abstract><title>Abstract</title><sec id="hiv13733-sec-0001"><title>Objectives</title><p>Our aim was to examine mortality trends in the era of antiretroviral therapy, among people who inject drugs (PWID) who are living with HIV. The study objectives were to assess and quantify mortality among PWID diagnosed with HIV over time in Scotland, in the context of a recent outbreak of HIV and rise in drug&#x02010;related mortality.</p></sec><sec id="hiv13733-sec-0002"><title>Methods</title><p>This was a retrospective cohort study of those diagnosed with HIV in Scotland between January 2000 and February 2020, with acquisition related to injecting drug use, linked to mortality data. Factors associated with all&#x02010;cause mortality were examined using Cox proportional hazards regression.</p></sec><sec id="hiv13733-sec-0003"><title>Results</title><p>Among 430 individuals with 3143 person&#x02010;years (py) of follow&#x02010;up, 88 (20.5%) died. Drug&#x02010;related deaths accounted for 45.5% of all deaths, rising to 60% among those diagnosed in 2015&#x02013;2020. The crude all&#x02010;cause mortality was 28.00 per 1000 py overall and 37.62 per 1000 py within 5&#x02009;years of diagnosis. Mortality risk was markedly higher among PWID diagnosed in 2015&#x02013;2020 [adjusted hazard ratio (aHR) =&#x02009;3.53], relative to those diagnosed in 2000&#x02013;2004. Among those diagnosed in 2015&#x02013;2020 (as part of the HIV outbreak), the mortality risk was higher among those not on, compared with those on, opioid agonist therapy (aHR&#x02009;=&#x02009;3.87).</p></sec><sec id="hiv13733-sec-0004"><title>Conclusion</title><p>Mortality among PWID living with HIV in Scotland has risen substantially in the 21st century. Our findings highlight the important role of opioid&#x02010;agonist therapy, alongside other prevention and treatment measures to address high levels of drug&#x02010;related mortality for PWID living with HIV, including within HIV outbreaks in this population group.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="hiv13733-kwd-0001">drug&#x02010;related death</kwd><kwd id="hiv13733-kwd-0002">HIV</kwd><kwd id="hiv13733-kwd-0003">mortality</kwd><kwd id="hiv13733-kwd-0004">people who inject drugs</kwd></kwd-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="10"/><word-count count="6100"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.3 mode:remove_FC converted:01.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="hiv13733-cit-9001">
<string-name>
<surname>Metcalfe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Fraser</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Trayner</surname>
<given-names>KMA</given-names>
</string-name>, et al. <article-title>Rising mortality among people who inject drugs living with <styled-content style="fixed-case" toggle="no">HIV</styled-content> in <styled-content style="fixed-case" toggle="no">Scotland</styled-content>, <styled-content style="fixed-case" toggle="no">UK</styled-content>: A 20&#x02010;year retrospective cohort study</article-title>. <source>HIV Med</source>. <year>2025</year>;<volume>26</volume>(<issue>2</issue>):<fpage>265</fpage>&#x02010;<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.1111/hiv.13733</pub-id>
</mixed-citation>
</p></notes></front><body id="hiv13733-body-0001"><sec id="hiv13733-sec-0005"><title>INTRODUCTION</title><p>Mortality in people living with HIV (PLWH) is declining, with improvements in availability of antiretroviral therapy (ART) leading to increased rates of viral suppression, increasing HIV testing and efforts to engage people in lifelong care, resulting in life expectancy similar to the general population [<xref rid="hiv13733-bib-0001" ref-type="bibr">1</xref>]. However, findings from a recent collaborative observational cohort study in Europe and North America found that among people who inject drugs (PWID) living with HIV, all&#x02010;cause mortality (ACM) declines were minimal in men (4% decrease over time), and for women the mortality rate increased by 7% [<xref rid="hiv13733-bib-0002" ref-type="bibr">2</xref>] between 1996 and 2020.</p><p>People who inject drugs (PWID) are at increased risk of HIV acquisition through sharing of injecting equipment and sexual transmission [<xref rid="hiv13733-bib-0003" ref-type="bibr">3</xref>, <xref rid="hiv13733-bib-0004" ref-type="bibr">4</xref>]. In 2013, a systematic review [<xref rid="hiv13733-bib-0005" ref-type="bibr">5</xref>] demonstrated that among PWID, the ACM rate for those living with HIV was three times higher than for PWID who are HIV&#x02010;negative [<xref rid="hiv13733-bib-0005" ref-type="bibr">5</xref>]. This increased mortality rate is not explained by HIV&#x02010;related mortality alone, with the study showing no difference in mortality rates from drug overdose and AIDS in this group [<xref rid="hiv13733-bib-0005" ref-type="bibr">5</xref>]. The same authors demonstrated that non&#x02010;HIV/AIDS&#x02010;related mortality rate in PWID living with HIV in high&#x02010;income settings was 2.34 per 100 person&#x02010;years (py); more than 1.5 times higher than in PWID who are HIV&#x02010;negative [<xref rid="hiv13733-bib-0006" ref-type="bibr">6</xref>]. Furthermore, PWID living with HIV have double the drug&#x02010;related mortality rate than those who are HIV&#x02010;negative [<xref rid="hiv13733-bib-0006" ref-type="bibr">6</xref>]. Additionally, in 2024, Trickey et al. [<xref rid="hiv13733-bib-0002" ref-type="bibr">2</xref>] reported that drug&#x02010;related mortality had increased over time in PLWH in North America, but decreased in Europe. Although there was an overall cohort reduction (adjusted cause&#x02010;specific mortality rate ratio&#x02009;=&#x02009;0.94) the rates fluctuated over the 25&#x02010;year study period [<xref rid="hiv13733-bib-0002" ref-type="bibr">2</xref>]. These data suggest that PWID living with HIV are at risk of increased mortality that is not mediated entirely through HIV/AIDS, and thus other interventions in addition to ART are required to reduce harm in this population group.</p><p>One of the largest and most persistent recent HIV outbreaks among PWID in the UK was recorded in Glasgow, Scotland's largest city [<xref rid="hiv13733-bib-0003" ref-type="bibr">3</xref>]. Since 2015, prevalence of HIV among PWID in Glasgow City has risen more than 10&#x02010;fold, associated with homelessness, a rise in cocaine injecting as well as injecting in public places [<xref rid="hiv13733-bib-0004" ref-type="bibr">4</xref>, <xref rid="hiv13733-bib-0007" ref-type="bibr">7</xref>], with approximately 200 new diagnoses (at the time of writing). The public health response to this HIV outbreak has included efforts to increase access to harm reduction services, scale&#x02010;up of HIV testing in key services, an enhanced model of outreach HIV care, extended partner notification and the dispensing of ART alongside opioid&#x02010;agonist therapy (OAT) via community pharmacies [<xref rid="hiv13733-bib-0008" ref-type="bibr">8</xref>, <xref rid="hiv13733-bib-0009" ref-type="bibr">9</xref>].</p><p>Concurrently, drug&#x02010;related deaths in Scotland have increased rapidly since 2014 to one of the highest rates internationally [<xref rid="hiv13733-bib-0010" ref-type="bibr">10</xref>]. Glasgow has one of the highest drug&#x02010;related death (DRD) rates in Scotland [<xref rid="hiv13733-bib-0011" ref-type="bibr">11</xref>] and reviewing the interactions between both of these ongoing public health crises is fundamental to inform responses to prevent morbidity and mortality among PWID in Scotland. DRD in Scotland include those where the underlying cause of death was due to psychoactive substance use poisoning and where a drug listed under the Misuse of Drugs Act (1971) was known to be present in the body at the time of death [<xref rid="hiv13733-bib-0011" ref-type="bibr">11</xref>].</p><p>The rise in drug&#x02010;related harms has occurred despite widespread access to the evidence&#x02010;based harm reduction interventions in Scotland [<xref rid="hiv13733-bib-0012" ref-type="bibr">12</xref>, <xref rid="hiv13733-bib-0013" ref-type="bibr">13</xref>], including needle and syringe programmes (NSPs), OAT and widening access to naloxone. Other interventions, such as safe consumption facilities and drug&#x02010;checking services, are also recommended in international guidance [<xref rid="hiv13733-bib-0014" ref-type="bibr">14</xref>], but have yet to be implemented.</p><p>For PWID living with HIV, adherence to ART is key to reducing the risk of HIV&#x02010;related morbidity and mortality [<xref rid="hiv13733-bib-0001" ref-type="bibr">1</xref>]. Adapted HIV care service models in Glasgow have successfully supported high levels of ART adherence and viral suppression in PWID diagnosed during the HIV outbreak [<xref rid="hiv13733-bib-0008" ref-type="bibr">8</xref>]. This is in line with recommendations since 2015 of ART for all PLWH, regardless of stage of infection, combined with retention in care, to reduce all&#x02010;cause morbidity and mortality [<xref rid="hiv13733-bib-0015" ref-type="bibr">15</xref>, <xref rid="hiv13733-bib-0016" ref-type="bibr">16</xref>].</p><p>The aim of our study was to examine mortality trends in the era of ART, specifically among PWID, and during an outbreak of HIV. The study objectives were to assess and quantify mortality among PWID diagnosed with HIV over time in Scotland, with a particular focus on PWID diagnosed as part of the HIV outbreak in Glasgow.</p></sec><sec sec-type="methods" id="hiv13733-sec-0006"><title>METHODS</title><sec id="hiv13733-sec-0007"><title>Study design, data sources and study cohort</title><p>We conducted a retrospective cohort study of those living with HIV in Scotland diagnosed between January 2000 and February 2020 (relating to the pre&#x02010;COVID period). Inclusion criteria for cohort entry was a presumed route of HIV acquisition related to injecting drug use. This route of HIV acquisition is self&#x02010;reported by the person at diagnosis and therefore includes all those who reported injecting drug use, including men who have sex with men (MSM). Individuals were identified within the Public Health Scotland (PHS) national HIV diagnosis database, which contains a record of all individuals diagnosed with HIV in Scotland since 1988 [<xref rid="hiv13733-bib-0017" ref-type="bibr">17</xref>]. All individuals who receive healthcare in Scotland have a unique identifier known as the Community Health Index (CHI) number [<xref rid="hiv13733-bib-0018" ref-type="bibr">18</xref>]. Using CHI, the HIV diagnosis database was linked to National Records of Scotland (NRS) death records (Scotland's national death registry) to obtain mortality information, including date and cause of death. To obtain data on hepatitis C virus (HCV) coinfection, HIV diagnosis records were further linked to national records for HCV testing and diagnosis held at PHS [<xref rid="hiv13733-bib-0019" ref-type="bibr">19</xref>].</p><p>HIV diagnoses, for those with injecting drug use as a risk factor, were also linked to the Scottish National Prescribing Information System (PIS) which contains a record of all drugs which are paid for, prescribed and dispensed in the community in Scotland [<xref rid="hiv13733-bib-0020" ref-type="bibr">20</xref>]. Data were extracted relating to the prescription of OAT for opioid dependence (i.e. methadone, buprenorphine and buprenorphine/naloxone) since 2010. To define the exposure, as per other studies [<xref rid="hiv13733-bib-0010" ref-type="bibr">10</xref>], the date of reimbursement was used to determine periods on/off OAT (Supplementary File <xref rid="hiv13733-supitem-0001" ref-type="supplementary-material">S1</xref>).</p><p>Approval for record linkage of UK National Health Service (NHS) data was provided by the NHS Public Benefit and Privacy Panel for Health and Social Care (PBPP 2021&#x02013;0203).</p></sec><sec id="hiv13733-sec-0008"><title>Outcomes and exposures</title><p>The primary outcome measure for this study was all&#x02010;cause mortality (ACM). Secondary outcome measures included drug&#x02010;related deaths and HIV&#x02010;related deaths. International Classification of Disease&#x02010;10 (ICD&#x02010;10) codes for underlying causes of death are described in Supplementary File&#x000a0;<xref rid="hiv13733-supitem-0001" ref-type="supplementary-material">S1</xref>, Table&#x000a0;<xref rid="hiv13733-tbl-0001" ref-type="table">1</xref>.</p><p>Exposure variables included: years since diagnosis (0&#x02013;5&#x02009;years/6&#x02013;10/11+ years); age (continuous); sex (male/female); OAT status (on or off; time varying); time period of diagnosis (2000&#x02013;2004/2005&#x02013;2009/2010&#x02013;2014/2015&#x02013;2020); HCV status (never diagnosed/diagnosed with anti&#x02010;HCV antibodies).</p></sec><sec id="hiv13733-sec-0009"><title>Statistical analysis</title><sec id="hiv13733-sec-0010"><title>Factors associated with mortality among <styled-content style="fixed-case" toggle="no">PWID</styled-content> diagnosed with <styled-content style="fixed-case" toggle="no">HIV</styled-content> in Scotland (2000&#x02013;2020)</title><p>Mortality rates were quantified for the analysis period 1 January 2000 through to 29 February 2020. Persons&#x02010;years was calculated from date of HIV diagnosis to the earliest of either date of death or 29 February 2020. We first estimated crude mortality rates overall and stratified by key demographics and comorbidities: calendar period of diagnosis, sex, age and HCV status.</p><p>Cause of death (DRD/HIV/other) by calendar period of HIV diagnosis, censored at 5&#x02009;years since diagnosis, was reported as there was limited follow&#x02010;up time for those more recently diagnosed.</p><p>We fitted univariate and multivariate Cox proportional hazard regression models to estimate unadjusted and adjusted hazard ratios, respectively, of ACM associated with a parsimonious set of key covariates covering era, demographics and factors known to increase risk of mortality among PLWH: time period of diagnosis, sex, age and HCV status (diagnosed/undiagnosed).</p><p>To address the issue of longer follow&#x02010;up for those diagnosed earlier in the study period, we conducted a sensitivity analysis, censoring follow&#x02010;up time at 5&#x02009;years after diagnosis. HCV status was not included in the sensitivity analysis due to lack of statistical power.</p><p>In supplementary analysis, we replaced the main exposure variable (calendar period of diagnosis), with a &#x02018;years since diagnosis&#x02019; variable (0&#x02013;5/6+ years) and confined analysis to those diagnosed prior to 2015, therefore excluding those with less than 5&#x02009;years follow&#x02010;up available. This was to further assess if there was evidence of a high&#x02010;risk period of mortality shortly after diagnosis with HIV, which may be due to late diagnosis of HIV or other drug&#x02010;related harms around the time of HIV diagnosis.</p><p>Furthermore, we calculated crude mortality rates and univariate hazard ratios, using Cox proportional hazard regression models, for both drug&#x02010;related and HIV&#x02010;related deaths, by calendar period of HIV diagnosis, to determine if trends were driven by one specific cause of death.</p><p>We also calculated the rates of ACM by calendar time period to illustrate when the deaths occurred.</p></sec><sec id="hiv13733-sec-0011"><title>Factors associated with mortality among <styled-content style="fixed-case" toggle="no">PWID</styled-content> diagnosed with <styled-content style="fixed-case" toggle="no">HIV</styled-content> in Glasgow (during the <styled-content style="fixed-case" toggle="no">HIV</styled-content> outbreak period 2015&#x02013;2020)</title><p>To assess factors associated with mortality within the outbreak cohort in Glasgow, we restricted follow&#x02010;up time to begin on 1 January 2015 (when the outbreak was first identified) and included those diagnosed within the regional NHS Board (NHS Greater Glasgow &#x00026; Clyde). In multivariable analysis we considered OAT exposure (on OAT vs. off OAT; time&#x02010;varying), sex and age.</p></sec></sec></sec><sec sec-type="results" id="hiv13733-sec-0012"><title>RESULTS</title><sec id="hiv13733-sec-0013"><title>Cohort characteristics and mortality</title><p>The cohort consisted of 430 individuals who were diagnosed with HIV in Scotland between 1 January 2000 and 29 February 2020 with 3143 py of follow&#x02010;up. Approximately two&#x02010;thirds (62.6%) were male and most (83%) were aged 45 or under at the time of diagnosis (Table&#x000a0;<xref rid="hiv13733-tbl-0001" ref-type="table">1</xref>).</p><table-wrap position="float" id="hiv13733-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Characteristics of people who inject drugs who were diagnosed with HIV infection in Scotland during 2000&#x02013;2020.<xref rid="hiv13733-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th colspan="2" align="left" valign="bottom" rowspan="1">Characteristic</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">N</italic> (%)</th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="top" rowspan="1">All</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">430 (100.0%)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">161 (37.44%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">269 (62.56%)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Age group (years)<xref rid="hiv13733-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c;35</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">183 (42.56%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">36&#x02013;45</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">173 (40.23%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x0003e;45</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">74 (17.21%)</td></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Time period<xref rid="hiv13733-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">2000&#x02013;2004</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">89 (20.70%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2005&#x02013;2009</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">69 (16.05%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2010&#x02013;2014</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">85 (19.77%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2015&#x02013;2020<sup>a</sup>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">187 (43.49%)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">Time since HIV diagnosis<xref rid="hiv13733-note-0002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">0&#x02013;5&#x02009;years</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">236 (54.88%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">6&#x02013;10&#x02009;years</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">75 (17.44%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">11&#x02009;+&#x02009;years</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">119 (27.67%)</td></tr><tr><td rowspan="3" align="left" valign="top" colspan="1">CD4 count (cells/&#x003bc;L)<xref rid="hiv13733-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Low &#x0003c;500</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">266 (61.86%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">High &#x0003e;500</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">122 (28&#x000b7;37%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Missing</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">42 (9.77%)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Region<xref rid="hiv13733-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">NHS Greater Glasgow and Clyde board area</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">222 (51.63%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rest of Scotland</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">208 (48.37%)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">HCV status<xref rid="hiv13733-note-0003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td><td align="left" valign="top" rowspan="1" colspan="1">Not diagnosed</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">135 (31&#x000b7;40%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diagnosed with anti&#x02010;HCV (not chronic)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">295 (68.60%)</td></tr><tr><td rowspan="7" align="left" valign="top" colspan="1">Deaths by cause</td><td align="left" valign="top" rowspan="1" colspan="1">All&#x02010;cause</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">88 (20.47%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Drug&#x02010;related</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">40 (9.30%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HIV&#x02010;related</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12 (2.79%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver disease/liver cancer</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (2.09%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Non&#x02010;communicable diseases (cancer, heart disease, lung disease)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12 (2.79%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Suicide (including undetermined intent)</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6 (1.40%)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other causes</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9 (2.09%)</td></tr></tbody></table><table-wrap-foot id="hiv13733-ntgp-0001"><fn id="hiv13733-note-0001"><p>Abbreviations: HCV, hepatitis C virus.</p></fn><fn id="hiv13733-note-0002"><label>
<sup>a</sup>
</label><p>Follow&#x02010;up period ends on 29 Feb 2020.</p></fn><fn id="hiv13733-note-0003"><label>
<sup>b</sup>
</label><p>At time of HIV diagnosis.</p></fn></table-wrap-foot></table-wrap><p>There were 88 deaths within the study period, accounting for 20.5% of the overall cohort (Table&#x000a0;<xref rid="hiv13733-tbl-0001" ref-type="table">1</xref>). Drug&#x02010;related deaths (DRDs) accounted for nearly half (45.5%) of all deaths, with HIV&#x02010;related deaths accounting for 13.6% (Table&#x000a0;<xref rid="hiv13733-tbl-0001" ref-type="table">1</xref>).</p><p>When observing underlying causes of death by calendar period of diagnosis, censored at 5&#x02009;years of follow&#x02010;up, the proportion of DRDs increased from approximately 33% (three deaths) in those diagnosed in 2000&#x02013;2004, to around 60% (16 deaths) of the total deaths of those diagnosed in 2015&#x02013;2020 (Figure&#x000a0;<xref rid="hiv13733-fig-0001" ref-type="fig">1</xref>). The overall crude mortality rate (CMR) in the cohort was 28.00 [95% confidence interval (CI): 22.70&#x02013;34.51] per 1000 py (Table&#x000a0;<xref rid="hiv13733-tbl-0002" ref-type="table">2</xref>).</p><fig position="float" fig-type="FIGURE" id="hiv13733-fig-0001"><label>FIGURE 1</label><caption><p>Crude mortality rates by period of HIV diagnosis, censored at 5&#x02009;years after diagnosis.</p></caption><graphic xlink:href="HIV-26-265-g001" position="anchor" id="jats-graphic-1"/></fig><table-wrap position="float" id="hiv13733-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Factors associated with all&#x02010;cause mortality among HIV&#x02010;diagnosed people who inject drugs (2000&#x02013;2020<xref rid="hiv13733-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th colspan="2" align="left" valign="bottom" rowspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Deaths (<italic toggle="yes">n</italic>)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Person&#x02010;years (py)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mortality rate per 1000 py (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Unadjusted hazard ratio<xref rid="hiv13733-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref> (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Adjusted hazard ratio<xref rid="hiv13733-note-0006" ref-type="table-fn">
<sup>b</sup>
</xref>, <xref rid="hiv13733-note-0007" ref-type="table-fn">
<sup>c</sup>
</xref> (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="top" rowspan="1">Overall</td><td align="char" char="." valign="top" rowspan="1" colspan="1">88</td><td align="char" char="." valign="top" rowspan="1" colspan="1">3142.7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">28.00 (22.72&#x02013;34.51)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td rowspan="4" align="left" valign="top" colspan="1">Time period of HIV diagnosis</td><td align="left" valign="top" rowspan="1" colspan="1">2000&#x02013;2004</td><td align="char" char="." valign="top" rowspan="1" colspan="1">23</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1361.5</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">16.89 (11.23&#x02013;25.42)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (ref)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1 (ref)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2005&#x02013;2009</td><td align="char" char="." valign="top" rowspan="1" colspan="1">19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">745.6</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">25.48 (16.25&#x02013;39.95)</td><td align="left" valign="top" rowspan="1" colspan="1">1.87 (0.95&#x02013;3.70)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.072</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1.60 (0.80&#x02013;3.20)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.181</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2010&#x02013;2014</td><td align="char" char="." valign="top" rowspan="1" colspan="1">19</td><td align="char" char="." valign="top" rowspan="1" colspan="1">552.3</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">34.40 (21.94&#x02013;53.93)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>2.88 (1.36&#x02013;6.09)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.006</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>2.22 (1.03&#x02013;4.79)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.043</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2015&#x02013;2020<xref rid="hiv13733-note-0005" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">27</td><td align="char" char="." valign="top" rowspan="1" colspan="1">483.1</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">55.89 (38.33&#x02013;81.49)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>4.96 (2.23&#x02013;11.00)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>&#x0003c;0.001</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>3.53 (1.55&#x02013;8.03)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.003</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Age (continuous)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>1.03 (1.01&#x02013;1.06)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.010</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1.02 (0.99&#x02013;1.05)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">0.145</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="char" char="." valign="top" rowspan="1" colspan="1">57</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1822.7</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">31.27 (24.12&#x02013;40.54)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (ref)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1 (ref)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="char" char="." valign="top" rowspan="1" colspan="1">31</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1319.9</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">23.49 (16.52&#x02013;33.40)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>0.75 (0.48&#x02013;1.16)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.195</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>0.93 (0.59&#x02013;1.45)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.736</p>
</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">HCV status (time&#x02010;dependent)</td><td align="left" valign="top" rowspan="1" colspan="1">Not diagnosed</td><td align="char" char="." valign="top" rowspan="1" colspan="1">12</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1010.6</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">11.87 (6.74&#x02013;20.91)</td><td align="left" valign="top" rowspan="1" colspan="1">1 (ref)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">1 (ref)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Diagnosed</td><td align="char" char="." valign="top" rowspan="1" colspan="1">76</td><td align="char" char="." valign="top" rowspan="1" colspan="1">2132.1</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">35.65 (28.47&#x02013;44.63)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>2.88 (1.56&#x02013;5.33)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.001</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>2.28 (1.21&#x02013;4.30)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.011</p>
</td></tr></tbody></table><table-wrap-foot id="hiv13733-ntgp-0002"><fn id="hiv13733-note-0004"><p>Abbreviations: CI, confidence interval; HCV, hepatitis C virus.</p></fn><fn id="hiv13733-note-0005"><label>
<sup>a</sup>
</label><p>Follow&#x02010;up period ends on 29 February 2020.</p></fn><fn id="hiv13733-note-0006"><label>
<sup>b</sup>
</label><p>Modelled using Cox proportional hazard models.</p></fn><fn id="hiv13733-note-0007"><label>
<sup>c</sup>
</label><p>Adjusted for age, sex and HCV status.</p></fn></table-wrap-foot></table-wrap><sec id="hiv13733-sec-0014"><title>Factors associated with mortality among <styled-content style="fixed-case" toggle="no">PWID</styled-content> diagnosed with <styled-content style="fixed-case" toggle="no">HIV</styled-content> in Scotland (2000&#x02013;2020)</title><p>There was a substantial increase in mortality according to calendar period of diagnosis, with CMRs increasing from 16.89 (11.23&#x02013;25.42) per 1000 py in those diagnosed during 2000&#x02013;2004 to 55.89 (38.33&#x02013;81.49) per 1000 py in those diagnosed during 2015&#x02013;2020 (Table&#x000a0;<xref rid="hiv13733-tbl-0002" ref-type="table">2</xref>). In the multivariable model, this increasing trend over time remained after adjustment, with mortality risk in those diagnosed in 2015&#x02013;2020 over three times greater [adjusted hazard ratio (aHR) =&#x02009;3.53, 95% CI: 1.55&#x02013;8.03] than in 2000&#x02013;2004. Differences in mortality risk were less evident for both sex and age. For HCV status, being diagnosed with HCV had an increased risk of mortality compared with the never&#x02010;diagnosed group (aHR&#x02009;=&#x02009;2.28, 95% CI: 1.21&#x02013;4.30).</p><p>Supplementary analysis of ACM calculated by time period of death is shown in Supporting information, Supplementary File&#x000a0;<xref rid="hiv13733-supitem-0001" ref-type="supplementary-material">S3</xref>, Table&#x000a0;<xref rid="hiv13733-tbl-0002" ref-type="table">2</xref>. The number of deaths in each calendar time period increased over time but the mortality rate increase was not significant in the adjusted analysis.</p><p>For DRDs, there was evidence of an increasing trend of drug&#x02010;related mortality if diagnosed in a more recent calendar period, rising from 5.88 per 1000 py in 2000&#x02013;2004 to 33.12 per 1000 py in 2015&#x02013;2020 (HR&#x02009;=&#x02009;4.84, <italic toggle="yes">p</italic>&#x02009;=&#x02009;0.006). There was no evidence of an increase in HIV&#x02010;related deaths if diagnosed in a more recent calendar period, with these events much rarer (Table&#x000a0;<xref rid="hiv13733-tbl-0003" ref-type="table">3</xref>).</p><table-wrap position="float" id="hiv13733-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Crude mortality rates and hazard ratios for drug&#x02010;related deaths, HIV&#x02010;related deaths and other deaths among people who inject drugs (PWID) living with HIV (2000&#x02013;2020<xref rid="hiv13733-note-0010" ref-type="table-fn">
<sup>b</sup>
</xref>).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th colspan="5" align="left" valign="bottom" rowspan="1">Drug&#x02010;related deaths</th><th colspan="5" align="left" valign="bottom" rowspan="1">HIV&#x02010;related deaths</th><th colspan="5" align="left" valign="bottom" rowspan="1">Other deaths</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Number of deaths</th><th align="left" valign="bottom" rowspan="1" colspan="1">PYFU</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mortality rate per 1000 PYFU (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Unadjusted hazard ratio<xref rid="hiv13733-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref> (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Number of deaths</th><th align="left" valign="bottom" rowspan="1" colspan="1">PYFU</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mortality rate per 1000 PYFU (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Unadjusted hazard ratio<xref rid="hiv13733-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref> (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Number of deaths</th><th align="left" valign="bottom" rowspan="1" colspan="1">PYFU</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mortality rate per 1000 PYFU (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Unadjusted hazard ratio<xref rid="hiv13733-note-0009" ref-type="table-fn">
<sup>a</sup>
</xref> (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Overall</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>40</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>3142.7</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<p>12.73 (9.34&#x02013;17.35)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>12</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>3142.7</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<p>3.82 (2.17&#x02013;6.72)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>36</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>3142.7</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<p>11.46 (8.26&#x02013;15.88)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Time period of diagnosis</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">2000&#x02013;2004</td><td align="char" char="." valign="top" rowspan="1" colspan="1">8</td><td align="char" char="." valign="top" rowspan="1" colspan="1">1362</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.88 (2.94&#x02013;11.75)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1 (ref)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>2</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>1362</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">
<p>1.47 (0.37&#x02013;5.87)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1 (ref)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>13</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>1362</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9.55 (5.54&#x02013;16.44)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1 (ref)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>2005&#x02013;2009</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>7</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>745.6</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9.39 (4.48&#x02013;19.69)</td><td align="left" valign="top" rowspan="1" colspan="1">2.03 (0.69&#x02013;5.99)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.201</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>5</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>745.6</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">6.71 (2.79&#x02013;16.11)</td><td align="left" valign="top" rowspan="1" colspan="1">3.27 (0.64&#x02013;16.87)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.156</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>7</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>745.6</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">9.39 (4.48&#x02013;19.69)</td><td align="left" valign="top" rowspan="1" colspan="1">0.81 (0.32&#x02013;2.05)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.664</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>2010&#x02013;2014</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>9</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>552.3</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">16.29 (8.48&#x02013;31.32)</td><td align="left" valign="top" rowspan="1" colspan="1">3.80 (1.16&#x02013;12.50)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.028</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>3</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>552.3</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">5.43 (1.75&#x02013;16.84)</td><td align="left" valign="top" rowspan="1" colspan="1">1.76 (0.29&#x02013;10.56)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.536</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>7</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>552.3</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">12.67 (6.04&#x02013;26.58)</td><td align="left" valign="top" rowspan="1" colspan="1">1.17 (0.43&#x02013;3.14)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.758</p>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>2015&#x02013;2020<sup>2</sup>
</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>16</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>483.1</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">33.12 (20.29&#x02013;54.06)</td><td align="left" valign="top" rowspan="1" colspan="1">4.84 (1.56&#x02013;15.05)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.006</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>2</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>483.1</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">4.14 (1.04&#x02013;16.55)</td><td align="left" valign="top" rowspan="1" colspan="1">1.04 (0.14&#x02013;7.85)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.971</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>9</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>483.1</p>
</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">18.63 (9.69&#x02013;35.80)</td><td align="left" valign="top" rowspan="1" colspan="1">1.70 (0.60&#x02013;4.84)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.322</p>
</td></tr></tbody></table><table-wrap-foot id="hiv13733-ntgp-0003"><fn id="hiv13733-note-0008"><p>Abbreviations: CI, confidence interval; PYFU, person years follow.</p></fn><fn id="hiv13733-note-0009"><label>
<sup>a</sup>
</label><p>Modelled using Cox proportional hazard models.</p></fn><fn id="hiv13733-note-0010"><label>
<sup>b</sup>
</label><p>Follow&#x02010;up ends on 29 February 2020.</p></fn></table-wrap-foot></table-wrap><p>In sensitivity analysis, after censoring the follow&#x02010;up time to 5&#x02009;years post&#x02010;diagnosis, the trend of increasing mortality by calendar period of diagnosis was observed but we lack statistical power in multivariate analysis [HR&#x02009;=&#x02009;2.25 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.038) and aHR&#x02009;=&#x02009;1.88 (<italic toggle="yes">p</italic>&#x02009;=&#x02009;0.114)] (Supporting information Supplementary File&#x000a0;<xref rid="hiv13733-supitem-0001" ref-type="supplementary-material">S2</xref>, Table&#x000a0;<xref rid="hiv13733-tbl-0001" ref-type="table">1</xref>).</p><p>In the supplementary analysis, the risk of mortality was substantially higher in the 0&#x02013;5&#x02009;year period after diagnosis (aHR&#x02009;=&#x02009;1.54, 95% CI: 0.86&#x02010;2.76) compared with 6+ years since diagnosis (Supporting information, Supplementary File <xref rid="hiv13733-supitem-0001" ref-type="supplementary-material">S3</xref>, Table&#x000a0;<xref rid="hiv13733-tbl-0001" ref-type="table">1</xref>).</p></sec></sec><sec id="hiv13733-sec-0015"><title>Factors associated with mortality during the <styled-content style="fixed-case" toggle="no">HIV</styled-content> outbreak</title><p>The overall CMR for those diagnosed with HIV in Glasgow between 2015 and 2020 was 65.18 (95% CI: 43.69&#x02013;97.24) per 1000 py. (Table&#x000a0;<xref rid="hiv13733-tbl-0004" ref-type="table">4</xref>). There was substantially higher CMR for individuals who were off OAT (129.24, 95% CI: 7.92&#x02013;214.3 per 1000 py) compared with the on&#x02010;OAT group (36.43, 95% CI: 18.95&#x02013;70.01 per 1000 py). After adjustment for age and sex, the protective effect of OAT remained, with mortality risk among those off OAT being nearly four times greater (aHR&#x02009;=&#x02009;3.87, 95% CI: 1.66&#x02013;9.00) than among those on OAT. Females were shown to have increased risk of mortality (aHR&#x02009;=&#x02009;2.32, 95% CI: 1.02&#x02013;5.27) compared with males.</p><table-wrap position="float" id="hiv13733-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Factors associated with all&#x02010;cause mortality among people who inject drugs (PWID) diagnosed with HIV during the outbreak in Glasgow (2015&#x02013;2020<xref rid="hiv13733-note-0012" ref-type="table-fn">
<sup>a</sup>
</xref>).</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1"/><th align="left" valign="bottom" rowspan="1" colspan="1">Deaths (<italic toggle="yes">n</italic>)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Person&#x02010;years (py)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Mortality rate per 1000 py (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Unadjusted hazard ratio<xref rid="hiv13733-note-0012" ref-type="table-fn">
<sup>a</sup>
</xref> (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th><th align="left" valign="bottom" rowspan="1" colspan="1">Adjusted hazard ratio<xref rid="hiv13733-note-0013" ref-type="table-fn">
<sup>b</sup>
</xref>, <xref rid="hiv13733-note-0014" ref-type="table-fn">
<sup>c</sup>
</xref> (95% CI)</th><th align="left" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="top" rowspan="1">Overall</td><td align="char" char="." valign="top" rowspan="1" colspan="1">24</td><td align="char" char="." valign="top" rowspan="1" colspan="1">368.2</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">65.18 (43.69&#x02013;97.24)</td><td colspan="4" align="left" valign="top" rowspan="1"/></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">OAT status (time&#x02010;varying)</td><td align="left" valign="top" rowspan="1" colspan="1">On OAT</td><td align="char" char="." valign="top" rowspan="1" colspan="1">9</td><td align="char" char="." valign="top" rowspan="1" colspan="1">247.1</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">36.43 (18.95&#x02013;70.01)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1 (ref)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>1 (ref)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Off OAT</td><td align="char" char="." valign="top" rowspan="1" colspan="1">15</td><td align="char" char="." valign="top" rowspan="1" colspan="1">116.1</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">129.24 (77.92&#x02013;214.38)</td><td align="left" valign="top" rowspan="1" colspan="1">3.43 (1.49&#x02013;7.87)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.004</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">3.87 (1.66&#x02013;9.00)</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.002</p>
</td></tr><tr><td colspan="2" align="left" valign="top" rowspan="1">Age (continuous)</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>1.03 (0.97&#x02013;1.09)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.359</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1.03 (0.98&#x02013;1.09)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.298</p>
</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1">Male</td><td align="char" char="." valign="top" rowspan="1" colspan="1">12</td><td align="char" char="." valign="top" rowspan="1" colspan="1">239.4</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">50.13 (28.47&#x02013;88.26)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1 (ref)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">
<p>1 (ref)</p>
</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Female</td><td align="char" char="." valign="top" rowspan="1" colspan="1">12</td><td align="char" char="." valign="top" rowspan="1" colspan="1">128.8</td><td align="char" char="(" valign="top" rowspan="1" colspan="1">93.14 (52.90&#x02013;164.01)</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>1.86 (0.84&#x02013;4.15)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.127</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">
<p>2.32 (1.02&#x02013;5.27)</p>
</td><td align="char" char="." valign="top" rowspan="1" colspan="1">
<p>0.045</p>
</td></tr></tbody></table><table-wrap-foot id="hiv13733-ntgp-0004"><fn id="hiv13733-note-0011"><p>Abbreviations: CI, confidence interval; OAT, opioid&#x02010;agonist therapy.</p></fn><fn id="hiv13733-note-0012"><label>
<sup>a</sup>
</label><p>Follow&#x02010;up period ends on 29 February 2020.</p></fn><fn id="hiv13733-note-0013"><label>
<sup>b</sup>
</label><p>Modelled using Cox proportional hazard models.</p></fn><fn id="hiv13733-note-0014"><label>
<sup>c</sup>
</label><p>Adjusted for age and sex.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="hiv13733-sec-0016"><title>DISCUSSION</title><p>In the context of an HIV outbreak and high levels of drug&#x02010;related mortality, we quantified mortality among a cohort of individuals following their HIV diagnosis, with injecting drug use as the likely route of acquisition. We found that mortality among PWID living with HIV in Scotland has increased over a 20&#x02010;year period and was 3.5 times higher among those diagnosed in 2015&#x02013;2020 (relating to the outbreak period) than among those diagnosed in the early study period at the turn of the century. This is supported by the adjusted analysis of mortality by time period of death not showing an increase.</p><p>However, OAT was strongly protective against ACM among those diagnosed during the outbreak period, associated with a 75% reduction in risk. This is a similar finding to other studies [<xref rid="hiv13733-bib-0004" ref-type="bibr">4</xref>] and it should be acknowledged that whilst engaged with OAT, PWID are likely also to benefit from input from a range of other services, which may be protective.</p><p>Although sex was not a significant factor in the overall cohort, during the outbreak period, females were found to be an increased risk of mortality. This time period is recognized as an era of increased DRDs among women in Scotland with multiple possible contributing factors. [<xref rid="hiv13733-bib-0021" ref-type="bibr">21</xref>].</p><p>There is limited research to date quantifying mortality trends and factors associated with mortality specifically in PWID living with HIV, and less reporting on this in the context of an HIV outbreak. Scotland is a country with moderate to high coverage of the recommended harm reduction interventions to reduce morbidity and mortality in PWID, with extensive, free&#x02010;to&#x02010;access OAT, NSPs and naloxone [<xref rid="hiv13733-bib-0022" ref-type="bibr">22</xref>]. However, PWID need to access these services at levels that are high enough to prevent negative behaviours/risk associated with mortality, including DRD. In Glasgow, diamorphine&#x02010;assisted treatment was introduced towards the end of the study period [<xref rid="hiv13733-bib-0023" ref-type="bibr">23</xref>]. For people living with HIV, ART is provided free of charge on the NHS and as soon as possible after diagnosis, in line with national treatment guidance [<xref rid="hiv13733-bib-0024" ref-type="bibr">24</xref>] and services have adapted to a bespoke model of care for PWID [<xref rid="hiv13733-bib-0008" ref-type="bibr">8</xref>].</p><p>Despite these interventions, our study demonstrates a worrying increase in drug&#x02010;related mortality over time, with 60% of deaths among PWID living with HIV in 2015&#x02013;2020 deemed to be drug&#x02010;related. The overall CMR of 28 per 1000 py and peak CMR in 2015&#x02013;2020 of 55.89 per 1000 py far exceed the pooled estimates reported in previous cohort studies (2.35 per 100 py [<xref rid="hiv13733-bib-0005" ref-type="bibr">5</xref>], 11.1 per 1000 py) [<xref rid="hiv13733-bib-0002" ref-type="bibr">2</xref>].</p><p>Drug&#x02010;related mortality accounted for nearly half of the deaths within the HIV outbreak cohort. Scotland's DRD rate increased rapidly during the outbreak period partly due to changing polydrug use patterns, including increased use of non&#x02010;prescribed (&#x02018;street&#x02019;) benzodiazepines, gabapentinoids and injection of powder cocaine, alongside opioids [<xref rid="hiv13733-bib-0010" ref-type="bibr">10</xref>, <xref rid="hiv13733-bib-0025" ref-type="bibr">25</xref>, <xref rid="hiv13733-bib-0026" ref-type="bibr">26</xref>]. To our knowledge, this is the first study to report on the specific cause of death within recent HIV outbreak cohorts of PWID. The only other recent study to date examining mortality among PWID in the context of an HIV outbreak estimated ACM among PWID in Athens, Greece [<xref rid="hiv13733-bib-0027" ref-type="bibr">27</xref>]. They reported that HIV infection was associated with an increase in ACM and that PWID living with HIV had more than double (32.12) the standardized mortality ratio (SMR) than PWID who were HIV&#x02010;negative (14.00).</p><p>Despite high rates of DRDs, OAT was strongly protective against mortality during the outbreak and associated with a nearly four&#x02010;fold reduction in risk, supporting existing evidence [<xref rid="hiv13733-bib-0028" ref-type="bibr">28</xref>, <xref rid="hiv13733-bib-0029" ref-type="bibr">29</xref>]. This finding may be expected given the wider evidence of OAT effectiveness in PWID, and our study contributes to this evidence in the specific context of an HIV outbreak &#x02013; therefore demonstrating the importance of prioritizing OAT engagement and retention, alongside other key prevention intervention, such as NSPs, HIV testing and treatment, in the public health response to an HIV outbreak among PWID.</p><p>Our findings are in contrast to the improved survival overall for PLWH, due to widening access to ART and reduction in HIV/AIDS&#x02010;related deaths [<xref rid="hiv13733-bib-0001" ref-type="bibr">1</xref>]. However, more recently an increase in drug&#x02010;related mortality among PLWH has been also observed in North America [<xref rid="hiv13733-bib-0002" ref-type="bibr">2</xref>], where there is less OAT coverage, and for PWID living with HIV the authors reported an increase in mortality for women and a small decrease in men. These findings complement our study and demonstrate the importance of reporting on specific groups when examining mortality and causes in order to develop interventions to reduce mortality.</p><p>In Scotland, our findings demonstrate that policy&#x02010;makers must focus on further interventions to reduce drug&#x02010;related harms, including HIV. Although there is moderate to high coverage of harm reduction interventions [<xref rid="hiv13733-bib-0022" ref-type="bibr">22</xref>] and standards for medication&#x02010;assisted treatment [<xref rid="hiv13733-bib-0030" ref-type="bibr">30</xref>], further efforts are needed to enhance the prevention infrastructure, such as the introduction of safer drug consumption facilities and drug&#x02010;checking facilities for PWID; both of these interventions are scheduled for implementation in Scotland in 2024.</p><p>HIV prevention must be resourced within these structures as Scotland has committed to achieving HIV transmission elimination by 2030 [<xref rid="hiv13733-bib-0031" ref-type="bibr">31</xref>] and therefore a focus on widespread and frequent HIV testing, and early linkage to HIV care or HIV prevention measures (e.g. HIV pre&#x02010;exposure prophylaxis) with adapted service models to suit this vulnerable group are crucial. There has already been progress in this area in Glasgow [<xref rid="hiv13733-bib-0008" ref-type="bibr">8</xref>, <xref rid="hiv13733-bib-0032" ref-type="bibr">32</xref>] and there should be a commitment to continue this nationally to reduce HIV transmission and HIV&#x02010;related mortality in this group. The findings from the focused analysis on the outbreak cohort demonstrate the very high risk of mortality for those who acquired HIV during an outbreak, and that public health interventions must include prioritizing OAT, NSPs as well as treatment services for HIV and HCV.</p><p>For PWID living with HIV, it is reassuring that HIV&#x02010;related mortality is decreasing. However, in an era of ART for all and advances in ART, this cohort was still experiencing HIV&#x02010;related mortality in 2015&#x02013;2020. ART should be accessible to all, but Scottish data have shown that ART availability to PWID has been slower than other groups of PLWH [<xref rid="hiv13733-bib-0033" ref-type="bibr">33</xref>]. A recent scoping review [<xref rid="hiv13733-bib-0034" ref-type="bibr">34</xref>] confirmed this variability in achievement of ART adherence and viral suppression in PWID living with HIV. It found that although HIV/AIDS&#x02010;related mortality is decreasing in PWID, as with other groups, a gap remains for this group, who may also be impacted by compounding coinfections, such as hepatitis B and C and skin and soft tissue infections. It is important to highlight that there is no indication that ART use in this cohort contributed to deaths, and in the HIV outbreak cohort, the ART of choice included integrase inhibitors to minimize potential drug interactions.</p><p>If reduction in HIV&#x02010;related morbidity and mortality, and reduction in transmission overall in line with national and international goals [<xref rid="hiv13733-bib-0031" ref-type="bibr">31</xref>, <xref rid="hiv13733-bib-0035" ref-type="bibr">35</xref>] are to be achieved, it is important to understand more fully the mortality rate, and causes, among PWID living with HIV.</p><p>Furthermore, focusing on measures to reduce late HIV diagnosis and ensuring that treatment services can work with other key services to provide accessible ART for PWID in the early stages after HIV diagnosis are imperative, as we have shown the risk of mortality to be higher soon after diagnosis. This vulnerable group faces barriers to accessing traditional care models, especially due to stigma associated with injecting drug use [<xref rid="hiv13733-bib-0036" ref-type="bibr">36</xref>]. HIV treatment and prevention services must be able to adapt to provide services for treatment and monitoring, which integrate with other drug&#x02010;related harm prevention services, in order to reduce these barriers [<xref rid="hiv13733-bib-0008" ref-type="bibr">8</xref>].</p><p>Our study has a number of limitations. First, HIV acquisition risk is self&#x02010;reported by individuals via clinical services, and in some cases this is incomplete, which could lead to underreporting of numbers of PWID living with HIV in Scotland and exclusion from the study. Second, cause of death data are taken from death certificates and these are completed by the doctor who is certifying the death. The data were collated retrospectively and without full medical records, and therefore there is a possibility that inaccurate completion of the certificate could lead to HIV being coded as a direct cause of death rather than an indirect one. It is also possible that the HIV recording protocol on death certificates changed over the study time period, with potentially more recording of HIV in early time periods compared with later ones. The death certificates were not accessed in the study so it was not possible to adjust for this. Furthermore, in the sensitivity analysis, the trend of increasing mortality over the period of diagnosis, as seen in the primary model, diminished. This is probably due to the small numbers included in each time period in this analysis, resulting in a lack of statistical power.</p></sec><sec sec-type="conclusions" id="hiv13733-sec-0017"><title>CONCLUSION</title><p>Mortality among PWID living with HIV in Scotland has risen substantially in the 21st century. Our findings highlight the urgent need to sustain a multi&#x02010;intervention response to address the high levels of mortality in Scotland, and particularly in Glasgow, the setting of the UK's largest HIV outbreak among PWID in 30&#x02009;years. Without it, Scotland's pursuit of HIV transmission elimination and its &#x02018;national mission&#x02019; to reduce DRDs will be challenging, and health inequalities are likely to be widened among this most marginalized of populations.</p></sec><sec id="hiv13733-sec-0018"><title>AUTHOR CONTRIBUTIONS</title><p>RM, AMcA and SH designed the research idea. All authors contributed to data collection. RM, RF, KT, AMcA and SH interpreted the data and drafted the initial manuscript. All authors reviewed, made contributions and approved the final manuscript and all authors agree to be accountable for the work.</p></sec><sec sec-type="COI-statement" id="hiv13733-sec-0019"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="hiv13733-supitem-0001" position="float" content-type="local-data"><caption><p>
<bold>Data S1.</bold> Supporting information.</p></caption><media xlink:href="HIV-26-265-s001.docx"/></supplementary-material></sec></body><back><ref-list id="hiv13733-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="hiv13733-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="hiv13733-cit-0001">
<string-name>
<surname>Trickey</surname>
</string-name>, <string-name>
<surname>Sabin</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Burkholder</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>Life expectancy after 2015 of adults with HIV on long&#x02010;term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies</article-title>. <source>Lancet HIV</source>. <year>2023</year>;<volume>10</volume>(<issue>5</issue>):e295&#x02010;e307.</mixed-citation></ref><ref id="hiv13733-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="hiv13733-cit-0002">
<string-name>
<surname>Trickey A</surname>
</string-name>, <string-name>
<surname>McGinnis</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Gill</surname>
<given-names>MJ</given-names>
</string-name>, et al. <article-title>Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies</article-title>. <source>Lancet HIV</source>&#x000a0;<year>2024</year>;<volume>10</volume>(<issue>5</issue>):e295&#x02010;e307.</mixed-citation></ref><ref id="hiv13733-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="hiv13733-cit-0003">
<string-name>
<surname>Des Jarlais</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>Sypsa</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Feelemyer</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>HIV outbreaks among people who inject drugs in Europe, North America, and Israel</article-title>. <source>Lancet HIV</source>. <year>2020</year>;<volume>7</volume>(<issue>6</issue>):<fpage>e434</fpage>&#x02010;<lpage>e442</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2352-3018(20)30082-5</pub-id>
<pub-id pub-id-type="pmid">32504576</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="hiv13733-cit-0004">
<string-name>
<surname>McAuley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Palmateer</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>
<given-names>DJ</given-names>
</string-name>, et al. <article-title>Re&#x02010;emergence of HIV related to injecting drug use despite a comprehensive harm reduction environment: a cross&#x02010;sectional analysis</article-title>. <source>Lancet HIV</source>. <year>2019</year>;<volume>6</volume>(<issue>5</issue>):<fpage>e315</fpage>&#x02010;<lpage>e324</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2352-3018(19)30036-0</pub-id>
<pub-id pub-id-type="pmid">30981674</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="hiv13733-cit-0005">
<string-name>
<surname>Mathers</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Degenhardt</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bucello</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Lemon</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wiessing</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hickman</surname>
<given-names>M</given-names>
</string-name>. <article-title>Mortality among people who inject drugs: a systematic review and meta&#x02010;analysis</article-title>. <source>Bull World Health Organ</source>. <year>2013</year>;<volume>91</volume>(<issue>2</issue>):<fpage>102</fpage>&#x02010;<lpage>123</lpage>. doi:<pub-id pub-id-type="doi">10.2471/BLT.12.108282</pub-id>
<pub-id pub-id-type="pmid">23554523</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="hiv13733-cit-0006">
<string-name>
<surname>Mathers</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Degenhardt</surname>
<given-names>L</given-names>
</string-name>. <article-title>Examining non&#x02010;AIDS mortality among people who inject drugs</article-title>. <source>Aids</source>. <year>2014</year>;<volume>28 Suppl 4</volume>(<issue>4</issue>):<fpage>S435</fpage>&#x02010;<lpage>S444</lpage>. doi:<pub-id pub-id-type="doi">10.1097/QAD.0000000000000435</pub-id> PMID: 25409098; PMCID: PMC4247273.<pub-id pub-id-type="pmid">25409098</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="hiv13733-cit-0007">
<string-name>
<surname>Trayner</surname>
<given-names>KMA</given-names>
</string-name>, <string-name>
<surname>McAuley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Palmateer</surname>
<given-names>NE</given-names>
</string-name>, et al. <article-title>Increased risk of HIV and other drug&#x02010;related harms associated with injecting in public places: national bio&#x02010;behavioural survey of people who inject drugs</article-title>. <source>Int J Drug Policy</source>. <year>2020</year>;<volume>77</volume>:<elocation-id>102663</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2020.102663</pub-id> Epub 2020 Jan 22. PMID: 31981949; PMCID: PMC8330401.<pub-id pub-id-type="pmid">31981949</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="hiv13733-cit-0008">
<string-name>
<surname>Metcalfe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Ragonnet&#x02010;Cronin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bradley&#x02010;Stewart</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>From hospital to the community: redesigning the human immunodeficiency virus (HIV) clinical service model to respond to an outbreak of HIV among people who inject drugs</article-title>. <source>J Infect Dis</source>. <year>2020</year>;<volume>222</volume>(<issue>Suppl 5</issue>):<fpage>S410</fpage>&#x02010;<lpage>S419</lpage>. doi:<pub-id pub-id-type="doi">10.1093/infdis/jiaa336</pub-id>
<pub-id pub-id-type="pmid">32877546</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="hiv13733-cit-0009">
<string-name>
<surname>Trayner</surname>
<given-names>KMA</given-names>
</string-name>, <string-name>
<surname>Palmateer</surname>
<given-names>NE</given-names>
</string-name>, <string-name>
<surname>McAuley</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Evaluation of the scale&#x02010;up of HIV testing among people who inject drugs in Scotland in the context of an ongoing HIV outbreak</article-title>. <source>Int J Drug Policy</source>. <year>2021</year>;<volume>96</volume>:<elocation-id>103304</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103304</pub-id> Epub 2021 Jul 27. PMID: 34325970.<pub-id pub-id-type="pmid">34325970</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="hiv13733-cit-0010">
<string-name>
<surname>McAuley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fraser</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Glancy</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Mortality among individuals prescribed opioid&#x02010;agonist therapy in Scotland, UK, 2011&#x02010;20: a national retrospective cohort study</article-title>. <source>Lancet Public Health</source>. <year>2023</year>;<volume>8</volume>(<issue>7</issue>):<fpage>e484</fpage>&#x02010;<lpage>e493</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2468-2667(23)00082-8</pub-id> Epub 2023 Jun 7. PMID: 37295452.<pub-id pub-id-type="pmid">37295452</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0011"><label>11</label><mixed-citation publication-type="miscellaneous" id="hiv13733-cit-0011">
<collab collab-type="authors">National Records of Scotland</collab>
. <article-title>Drug&#x02010;related deaths in Scotland in 2022</article-title>. <year>2023</year>.</mixed-citation></ref><ref id="hiv13733-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="hiv13733-cit-0012">
<string-name>
<surname>Larney</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Peacock</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Leung</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Global, regional, and country&#x02010;level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review</article-title>. <source>Lancet Glob Health</source>. <year>2017</year>;<volume>5</volume>(<issue>12</issue>):<fpage>e1208</fpage>&#x02010;<lpage>e1220</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2214-109X(17)30373-X</pub-id>
<pub-id pub-id-type="pmid">29074410</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="hiv13733-cit-0013">
<string-name>
<surname>Wiessing</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ferri</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>B&#x0011b;l&#x000e1;&#x0010d;kov&#x000e1;</surname>
<given-names>V</given-names>
</string-name>, et al. <article-title>Monitoring quality and coverage of harm reduction services for people who use drugs: a consensus study</article-title>. <source>Harm Reduct</source>. <year>2017</year>;<volume>14</volume>:<fpage>19</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12954-0170141-6</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0014"><label>14</label><mixed-citation publication-type="book" id="hiv13733-cit-0014">
<collab collab-type="authors">World Health Organization, World Health Organization. Regional Office for Europe, UNAIDS &#x00026; United Nations. Office on Drugs and Crime</collab>
. <source>WHO, UNODC, UNAIDS Technical Guide for Countries to Set Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users</source>. <publisher-name>World Health Organization</publisher-name>; <year>2009</year>
<ext-link xlink:href="https://iris.who.int/handle/10665/44068" ext-link-type="uri">https://iris.who.int/handle/10665/44068</ext-link>
</mixed-citation></ref><ref id="hiv13733-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="hiv13733-cit-0015">
<string-name>
<surname>Lundgren</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Babiker</surname>
<given-names>AG</given-names>
</string-name>, <string-name>
<surname>Gordin</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>INSIGHT START study group. Initiation of antiretroviral therapy in early asymptomatic HIV infection</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>:<fpage>795</fpage>&#x02010;<lpage>807</lpage>.<pub-id pub-id-type="pmid">26192873</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="hiv13733-cit-0016">
<collab collab-type="authors">World Health Organisation</collab>
. <article-title>Guideline on when to start antiretroviral therapy and on pre&#x02010;exposure prophylaxis for HIV</article-title>. <year>2015</year>.</mixed-citation></ref><ref id="hiv13733-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="hiv13733-cit-0017">
<string-name>
<surname>Goldberg</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Emslie</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Smyth</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Reid</surname>
<given-names>D</given-names>
</string-name>. <article-title>A system for surveillance of voluntary HIV testing: results of the first 2&#x02009;years, 1989&#x02013;1990</article-title>. <source>Aids</source>. <year>1992</year>;<volume>6</volume>(<issue>5</issue>):<fpage>495</fpage>&#x02010;<lpage>500</lpage>.<pub-id pub-id-type="pmid">1616656</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0018"><label>18</label><mixed-citation publication-type="miscellaneous" id="hiv13733-cit-0018">
<collab collab-type="authors">Information Services Division</collab>
. <article-title>Community health index (CHI) number [WWW document]</article-title>. <year>2021</year> URL <ext-link xlink:href="https://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets//Patient-Identification-and-Demographic-Information/Community-Health-Index-Number/" ext-link-type="uri">https://www.ndc.scot.nhs.uk/Data-Dictionary/SMR-Datasets//Patient-Identification-and-Demographic-Information/Community-Health-Index-Number/</ext-link>
</mixed-citation></ref><ref id="hiv13733-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="hiv13733-cit-0019">
<string-name>
<surname>McLeod</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Hutchinson</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Increased case&#x02010;finding and uptake of direct&#x02010;acting antiviral treatment essential for micro&#x02010;elimination of hepatitis C among people living with HIV: a national record linkage study</article-title>. <source>HIV Med</source>. <year>2021</year>;<volume>22</volume>(<issue>5</issue>):<fpage>334</fpage>&#x02010;<lpage>345</lpage>. doi:<pub-id pub-id-type="doi">10.1111/hiv.13032</pub-id> Epub 2020 Dec 17. PMID: 33350049.<pub-id pub-id-type="pmid">33350049</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="hiv13733-cit-0020">
<string-name>
<surname>Alvarez&#x02010;Madrazo</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>McTaggart</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nangle</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Nicholson</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Bennie</surname>
<given-names>M</given-names>
</string-name>. <article-title>Data resource profile: the Scottish National Prescribing Information System (PIS)</article-title>. <source>Int J Epidemiol Oxford Acad</source>. <year>2016</year>;<volume>45</volume>(<issue>3</issue>):<fpage>714</fpage>&#x02010;<lpage>715f</lpage>.</mixed-citation></ref><ref id="hiv13733-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="hiv13733-cit-0021">
<string-name>
<surname>Tweed</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Miller</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Schofield</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Barnsdale</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Matheson</surname>
<given-names>C</given-names>
</string-name>. <article-title>Why are drug&#x02010;related deaths among women increasing in Scotland? A mixed&#x02010;methods analysis of possible explanations</article-title>. <source>Drugs (Abingdon Engl)</source>. <year>2022</year>;<volume>29</volume>(<issue>1</issue>):<fpage>62</fpage>&#x02010;<lpage>75</lpage>. doi:<pub-id pub-id-type="doi">10.1080/09687637.2020.1856786</pub-id> Epub 2020 Dec 11. PMID: 35095222; PMCID: PMC7612287.<pub-id pub-id-type="pmid">35095222</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="hiv13733-cit-0022">
<string-name>
<surname>Colledge&#x02010;Frisby</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ottaviano</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Webb</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Global coverage of interventions to prevent and manage drug&#x02010;related harms among people who inject drugs; a systematic review</article-title>. <source>Lancet Glob Health</source>. <year>2023</year>;<volume>11</volume>:<fpage>e673</fpage>&#x02010;<lpage>e683</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S2214-109X(23)00058-X</pub-id>
<pub-id pub-id-type="pmid">36996860</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0023"><label>23</label><mixed-citation publication-type="miscellaneous" id="hiv13733-cit-0023">
<collab collab-type="authors">Glasgow City Council News</collab>
. <article-title>Scotland's First Heroin Assisted Treatment Unveiled &#x02010; Glasgow City Council</article-title>. <year>2019</year>.</mixed-citation></ref><ref id="hiv13733-bib-0024"><label>24</label><mixed-citation publication-type="miscellaneous" id="hiv13733-cit-0024">
<string-name>
<surname>British</surname>
<given-names>HIV</given-names>
</string-name>. <article-title>Association. BHIVA guidelines on antiretroviral treatment for adults living with HIV&#x02010;1 2022 (2023 interim update). 2023. BHIVA&#x02010;guidelines&#x02010;on&#x02010;antiretroviral&#x02010;treatment&#x02010;for&#x02010;adults&#x02010;living&#x02010;with&#x02010;HIV&#x02010;1&#x02010;2022.pdf.pdf</article-title>.</mixed-citation></ref><ref id="hiv13733-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="hiv13733-cit-0025">
<string-name>
<surname>McAuley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Matheson</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Robertson</surname>
<given-names>JR</given-names>
</string-name>. <article-title>From the clinic to the street: the changing role of benzodiazepines in the Scottish overdose epidemic</article-title>. <source>Int J Drug Policy</source>. <year>2022</year>;<volume>100</volume>:<elocation-id>103512</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103512</pub-id> Epub 2021 Nov 6. PMID: 34753047.<pub-id pub-id-type="pmid">34753047</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="hiv13733-cit-0026">
<string-name>
<surname>Glancy</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Palmateer</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yeung</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Risk of drug&#x02010;related death associated with co&#x02010;prescribing of gabapentinoids and Z&#x02010;drugs among people receiving opioid&#x02010;agonist treatment: a national retrospective cohort study</article-title>. <source>Psychiatry Res</source>. <year>2024</year>;<volume>339</volume>:<elocation-id>116028</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.psychres.2024.116028</pub-id> Epub 2024 Jun 12. PMID: 38917674.<pub-id pub-id-type="pmid">38917674</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="hiv13733-cit-0027">
<string-name>
<surname>Roussos</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Angelopoulos</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Cholongitas</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>High levels of all&#x02010;cause mortality among people who inject drugs from 2018 to 2022</article-title>. <source>Int J Drug Policy</source>. <year>2024</year>;<volume>126</volume>:<elocation-id>104356</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2024.104356</pub-id>
<pub-id pub-id-type="pmid">38394950</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="hiv13733-cit-0028">
<string-name>
<surname>Degenhardt</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Grebely</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Stone</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Global patterns of opioid use and dependence: harms to populations, interventions, and future action</article-title>. <source>Lancet</source>. <year>2019</year>;<volume>394</volume>(<issue>10208</issue>):<fpage>1560</fpage>&#x02010;<lpage>1579</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(19)32229-9</pub-id>
<pub-id pub-id-type="pmid">31657732</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="hiv13733-cit-0029">
<string-name>
<surname>Vallecillo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Robles</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Dur&#x000e1;n</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Lerma</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Horcajada</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Torrens</surname>
<given-names>M</given-names>
</string-name>. <article-title>Trends in AIDS mortality, retention in opioid agonist therapy, and HIV RNA suppression in HIV&#x02010;infected people who injected drugs from 2000 to 2015</article-title>. <source>AIDS Behav</source>. <year>2018</year>;<volume>22</volume>(<issue>9</issue>):<fpage>2766</fpage>&#x02010;<lpage>2772</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s10461-018-2033-5</pub-id>
<pub-id pub-id-type="pmid">29372455</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0030"><label>30</label><mixed-citation publication-type="miscellaneous" id="hiv13733-cit-0030">
<collab collab-type="authors">Scottish Government</collab>
. <article-title>Medication Assisted Treatment (MAT) Standards: Access, Choice, Support</article-title>. <year>2021</year>
<ext-link xlink:href="https://www.gov.scot/publications/medication-assisted-treatment-mat-standards-scotland-access-choice-support/" ext-link-type="uri">https://www.gov.scot/publications/medication-assisted-treatment-mat-standards-scotland-access-choice-support/</ext-link>
</mixed-citation></ref><ref id="hiv13733-bib-0031"><label>31</label><mixed-citation publication-type="miscellaneous" id="hiv13733-cit-0031">
<collab collab-type="authors">Eliminating HIV transmission by 2030</collab>
. <article-title>Scottish Government</article-title>. <year>2020</year>
<ext-link xlink:href="https://www.gov.scot/news/eliminating-hiv-transmission-by-2030/" ext-link-type="uri">https://www.gov.scot/news/eliminating-hiv-transmission-by-2030/</ext-link>
</mixed-citation></ref><ref id="hiv13733-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="hiv13733-cit-0032">
<string-name>
<surname>Grimshaw</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Boyd</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Estcourt</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Metcalfe</surname>
<given-names>R</given-names>
</string-name>. <article-title>Evaluation of an inner city HIV pre&#x02010;exposure prophylaxis service tailored to the needs of people who inject drugs</article-title>. <source>HIV Med</source>. <year>2021</year>;<volume>22</volume>(<issue>10</issue>):<fpage>965</fpage>&#x02010;<lpage>970</lpage>. doi:<pub-id pub-id-type="doi">10.1111/hiv.13181</pub-id> Epub 2021 Sep 28. PMID: 34585494.<pub-id pub-id-type="pmid">34585494</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0033"><label>33</label><mixed-citation publication-type="miscellaneous" id="hiv13733-cit-0033">
<string-name>
<surname>Metcalfe</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>McAuley</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wallace L</surname>
</string-name>, et al. <article-title>Is early ART achievable in people who inject drugs (PWIDs) living with HIV? HIV Glasgow P079</article-title>.</mixed-citation></ref><ref id="hiv13733-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="hiv13733-cit-0034">
<string-name>
<surname>Uusk&#x000fc;la</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Feelemyer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Des Jarlais</surname>
<given-names>DC</given-names>
</string-name>. <article-title>HIV treatment, antiretroviral adherence and AIDS mortality in people who inject drugs: a scoping review</article-title>. <source>Eur J Public Health</source>. <year>2023</year>;<volume>33</volume>(<issue>3</issue>):<fpage>381</fpage>&#x02010;<lpage>388</lpage>. doi:<pub-id pub-id-type="doi">10.1093/eurpub/ckad008</pub-id>
<pub-id pub-id-type="pmid">36723859</pub-id>
</mixed-citation></ref><ref id="hiv13733-bib-0035"><label>35</label><mixed-citation publication-type="book" id="hiv13733-cit-0035">
<source>Global Health Sector Strategies on, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022&#x02013;2030</source>. <publisher-name>World Health Organization (WHO)</publisher-name>; <year>2022</year> Licence: CC BY&#x02010;NC&#x02010;SA 3.0 IGO. <ext-link xlink:href="https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/strategies/global-health-sector-strategies" ext-link-type="uri">https://www.who.int/teams/global&#x02010;hiv&#x02010;hepatitis&#x02010;and&#x02010;stis&#x02010;programmes/strategies/global&#x02010;health&#x02010;sector&#x02010;strategies</ext-link>
</mixed-citation></ref><ref id="hiv13733-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="hiv13733-cit-0036">
<string-name>
<surname>Paquette</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Syvertsen</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Pollini</surname>
<given-names>RA</given-names>
</string-name>. <article-title>Stigma at every turn: health services experiences among people who inject drugs</article-title>. <source>Int J Drug Policy</source>. <year>2018</year>;<volume>57</volume>:<fpage>104</fpage>&#x02010;<lpage>110</lpage>.<pub-id pub-id-type="pmid">29715589</pub-id>
</mixed-citation></ref></ref-list></back></article>